News
Novo Nordisk’s CagriSema Falls Short of 25% Weight Loss Target in Patients with Obesity or Overweight
Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults with overweight or obesity and a weight-related medical condition, but without diabetes.
CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Head-splitting migraines could be the next ailment in a seemingly endless list that a class of blockbuster weight-loss drugs ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...
While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...
A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...
The term sheet was signed in the presence of senior officials from BIRAC, the department of biotechnology, and industry ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback